Mechanistic understanding of dendritic cell activation in skin sensitization: additional evidences to support potency classification by V. Galbiati et al.
Journal Pre-proof
MECHANISTIC UNDERSTANDING OF DENDRITIC CELL ACTIVATION
IN SKIN SENSITIZATION: ADDITIONAL EVIDENCES TO SUPPORT
POTENCY CLASSIFICATION
Vlentina Galbiati, Marina Marinovich, Emanuela Corsini
PII: S0378-4274(20)30022-9
DOI: https://doi.org/10.1016/j.toxlet.2020.01.014
Reference: TOXLET 10683
To appear in: Toxicology Letters
Received Date: 7 October 2019
Revised Date: 14 January 2020
Accepted Date: 16 January 2020
Please cite this article as: Galbiati V, Marinovich M, Corsini E, MECHANISTIC
UNDERSTANDING OF DENDRITIC CELL ACTIVATION IN SKIN SENSITIZATION:
ADDITIONAL EVIDENCES TO SUPPORT POTENCY CLASSIFICATION, Toxicology Letters
(2020), doi: https://doi.org/10.1016/j.toxlet.2020.01.014
This is a PDF ﬁle of an article that has undergone enhancements after acceptance, such as
the addition of a cover page and metadata, and formatting for readability, but it is not yet the
deﬁnitive version of record. This version will undergo additional copyediting, typesetting and
review before it is published in its ﬁnal form, but we are providing this version to give early
visibility of the article. Please note that, during the production process, errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal
pertain.
© 2019 Published by Elsevier.
 1 
MECHANISTIC UNDERSTANDING OF DENDRITIC CELL ACTIVATION 
IN SKIN SENSITIZATION: ADDITIONAL EVIDENCES TO SUPPORT 
POTENCY CLASSIFICATION 
 
 Valentina Galbiati1, Marina Marinovich2 and Emanuela Corsini1 
 
1Laboratory of Toxicology, Department of Environmental and Political Sciences, 
Università degli Studi di Milano, Via Balzaretti 9, 20133 Milan, Italy 
2Laboratory of Toxicology, Department of Pharmacological and Biomolecular 
Sciences, Università degli Studi di Milano, Via Balzaretti 9, 20133 Milan, Italy 
 
Corresponding author: 
Valentina Galbiati 
Laboratory of Toxicology 
Department of Environmental Science and Policy 
Via Balzaretti 9 
20133 Milano - Italy 
Phone +39 02 50318368 
FAX +39 02 50318284 
e-mail: valentina.galbiati@unimi.it  
 
 
 
 
 
 
 
 
 
Jo
urn
al 
Pre
-pr
oo
f
 2 
Graphical abstract 
 
 
 
 
Highlights 
 The identification of mechanisms influencing allergen potency requires 
better understanding of molecular events that trigger cell activation 
 Allergens of different potency differently modulated cell surface markers 
expression, with HLA-DR induced only by extreme contact allergens 
 A central role is played by PKC beta II in the initiation of chemical allergen-
induced DC maturation and activation 
 
 
Abstract 
Allergic contact dermatitis (ACD) is an important occupational and environmental 
disease caused by topical exposure to chemical allergens. In the EU, it has been 
calculated that 4% of animals are used in toxicity test for the assessment of skin 
sensitization (1). To come a complete replacement of animals, evaluation of relative 
skin sensitization potency is necessary. The identification of mechanisms influencing 
allergen potency requires a better understanding of molecular events that trigger cell 
activation. Therefore, (i) the effects of selected allergens on surface markers expression 
and cytokines release in contact allergen-induced cell activation were assessed, and (ii) 
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the role of Protein Kinase C (PKC) beta activation in contact allergen-induced cell 
activation was investigated. The human pro-myelocytic cell line THP-1 was used as 
experimental model surrogate of dendritic cells. Cells were exposed to select contact 
allergens of different potency and cell surface marker expression (CD80, CD86, HLA-
DR) was determined by flow cytometry analysis. Cytokines production (IL-6, IL-8, IL-
10, IL-12p40, IL-18) was evaluated with specific sandwich ELISA. The effective 
contribution of PKC beta in chemical allergen-induced cell activation was assessed by 
Western Blot analysis (PKC beta activation) and using a specific PKC beta inhibitor 
(PKC beta pseudosubstrate). In addition, to investigate if contact allergens are able to 
induce indeed dendritic cells (DCs) maturation, THP-1 cells were differentiated to 
immature DC and then exposed to contact allergen of different potency. Overall, our 
finding provides insights into the process of sensitization and strength of cell 
activation associated with allergens of different potency. Results obtained suggest that 
contact allergens of different potency are able to induce a different degree of activation 
of dendritic cells maturation involved in the process of ACD. 
 
Keywords: in vitro method, potency, contact allergy, skin sensitisation, 
PKC beta 
 
Introduction 
Allergic contact dermatitis (ACD) is a form of delayed type hypersensitivity caused by 
small molecular weight chemicals (haptens) and mediate by the T cells (2,3). ACD can 
have serious impact on the quality of life and represents a common and important 
environmental and occupational health hazard. The adverse outcome pathways (AOPs) 
for ACD are reported in the OECD report where mechanisms understanding skin 
sensitization have been divided into different key events (KEs). The established KEs 
are: (i) covalent interaction of chemical to cells protein; (ii) activation of inflammatory 
cytokines and induction of cyto-protective gene pathways with the involvement of 
keratinocytes (KCs); (iii) induction of inflammatory cytokines and surface markers 
with the mobilization of the dendritic cells (DCs); (iv) activation, proliferation and 
polarization of T cells (4). 
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The evaluation of the contact sensitization potential of chemicals is currently done 
using the local lymph node assay (LLNA), as described in the OECD guideline 429. In 
addition, to the hazard identification, the LLNA has proven very useful in assessing the 
skin sensitizing potency of chemicals, based on the estimation of the concentration of 
chemical required to induce a stimulation index of three relative to concurrent vehicle-
treated controls (i.e., EC3 value). Low EC3 values correlated well with sensitizers 
known to be potent in human, whereas high EC3 values were usually associated with 
weakly human sensitizers (5).  Driven by the 7th Amendment to the EU Cosmetic 
Directive, the EU policy on chemicals (the REACH system), the update of the European 
legislation on the protection of animals used in research, and emerging visions and 
strategies for predicting toxicity, replacement of the LLNA is become an important 
issue. The identification of mechanisms influencing the vigor of T cell responses, that 
can explain the strength of ACD reactions to weak, moderate, strong, and extreme 
sensitizers (6,7) is a challenge still to be solved and this will require a better 
understanding of the molecular events that trigger cell activation following exposure to 
contact allergens. Contact sensitizers have been demonstrated to induce phenotypic and 
functional changes in DC with the up regulation of surface expression of major 
histocompatibility complex (MHC) class II molecules, co-stimulatory molecules (e.g. 
CD80, CD86, CD40 and CCR7) and cytokines, enhancing their antigen-presenting 
capacity that ultimately could modulate T cell response (8,9). DCs are a heterogeneous 
population of antigen-presenting cells (APC) that play a central role in the initiation 
and regulation of adaptive immune responses. It is generally assumed that three signals 
are required for the activation of naïve T helper cells. Signal 1 or stimulation: the 
recognition by the T-cell receptor (TCR) of antigenic peptides presented by MHC class 
II molecules expressed on DCs. Signal 2 or co-stimulation: provided by the triggering 
of CD28 on the T cell by CD80 and CD86 molecules on the DCs. Signal 3 or 
polarization: signals delivered from DCs, and other innate immune cells as well as 
epithelial cells, to T cell that determine its differentiation into various effector 
phenotypes such as Th1, Th2, Treg (10).  
It has been shown that protein kinase C (PKC) activation is necessary and sufficient to 
drive human CD34+ hematopoietic progenitor cells, peripheral blood monocytes or 
myeloid leukemic cell lines to DC differentiation (11). PKCs play a key regulatory role 
in a variety of cellular functions, including cell growth and differentiation, gene 
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expression, hormone secretion. Different PKC isoforms mediate specific cellular 
signals required for activation, proliferation, differentiation and survival of immune 
cells (12,13). Of the classical PKC isoforms, only PKC-βII has been shown to be 
consistently activated during DCs differentiation-inducing stimuli in normal and 
leukemic progenitors (11) PKC-βII activation by cytokines (GM-CSF, IL-4 and TNF-
α) in DCs was demonstrated to be associated with up-regulation of DCs surface markers 
(MHC I, MHC II, CD11c, CD40, CD80, CD83 and CD86), the induction of expression 
of the NF-κB family member c-Rel, and the ability to stimulate allogeneic T cell 
proliferation (14).  
Based on the concept and speculation that the extent of chemical allergen-induced DCs 
activation, maturation and lifespan drives the quality and magnitude of T cell activation 
and that PKC-β activation is necessary to drive DCs differentiation and is central to 
chemical allergen-induced DCs activation, the global aim of this work was to provide 
a mechanistic point of view able to support in vitro potency information, necessary for 
full replacement of animals in the assessment of the allergenic potential of xenobiotics.   
 
Materials and methods  
Chemicals  
p-benzoquinone (BZQ), Bandrowski’s base (BB), diethyl maleate (DEM), fluorescein 
isothiocyanate isomer I (FITC), α-hexylcinnamaldehyde (HCA), hydroxycitronellal 
(HDC), and imidazolidinyl urea (IMZ) were selected as skin sensitizers according to 
their LLNA potency (15). Chemicals were purchased from Sigma Aldrich and Apollo 
Scientific (Bandrowski’s base) at the highest purity available. BZQ, BB, DEM, HCA, 
and HDC were dissolved in dimethyl sulfoxide (DMSO) (final concentration of DMSO 
in culture medium <0.2%), while IMZ was dissolved in Dulbecco’s Phosphate Buffered 
Saline (dPBS). Cell culture media and all supplements were from Sigma Aldrich. The 
selected contact sensitizers were classified according to their potency on the basis of 
the EC3 LLNA value data, covering different potencies from extreme to weak (Table 
1).  
To investigate the role of PKC-β in chemical-induced cell surface markers expression 
and cytokines release, THP-1 cells were cultured for 2 h in the presence or absence of 
a selective cell-permeable inhibitor of PKC-β at 5 μM concentration (PKC-β 
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pseudosubstrate, Tocris, Bristol, UK) in culture medium cell without FCS.  
 
Cells  
THP-1. For all experiments, THP-1 cells (Istituto Zooprofilattico di Brescia, Brescia, 
Italy) were used at a cell density of 106 cells/mL in RPMI 1640 containing 2M 
glutamine, 0.1 mg/mL streptomycin, 100 UI/mL penicillin, 50 μM 2-mercaptoethanol, 
supplemented with 10% heated-inactivated foetal calf serum (media) and cultured at 
37°C in 5% CO2. For cytotoxicity, cytokines release and surface marker expression 10
6 
cells/ml (0.5 ml/well) were seeded in 24-well plates and incubated with increasing 
concentrations of the selected chemicals or DMSO as vehicle control for 24, 48 and 
72h. In dose-response experiments, cells were treated using the CV75 as the highest 
concentration and with two two-fold dilutions for a total of three concentrations. CV75 
represent the concentration resulting in a cell viability of 75% compared to vehicle-
treated cells. In time-course experiments, cells were exposed for 24, 48 and 72h to one 
concentration for each chemical (half of the CV75 to avoid excessive cytotoxicity as 
cells were cultured up to 72h). 
 
DC differentiation. For DC differentiation, THP-1 cells were treated for 5 days with 
rhIL-4 (1500 UI/mL – R&D Systems) and rhGM-CSF (1500 UI/mL – ImmunoTools 
GmbH) to acquire the properties of immature DCs (iDCs) as described by Berges et al. 
(2005) (16). Mature DCs were then generated from iDCs by addition of rhIL-4 (3000 
UI/mL), rhTNF-α (2000 UI/mL – Sigma Aldrich) and ionomycin (200 ng/mL – Sigma 
Aldrich) or by exposure to the selected contact allergen (BB, DEM and HCA) for 24, 
48 and 72h. As markers of DCs differentiation and maturation CD40, CD80, CD86, 
and HLA-DR (BD, Becton Dickinson and ImmunoTools) were assessed by FACS 
analysis as described below.  
 
Cell viability 
THP-1 cells were treated for 24h with increasing concentrations of the selected 
chemicals starting from their maximum solubility in appropriate solvents (i.e. DMSO 
or PBS) and typically with 12 subsequent two-fold dilutions. Cell viability was assessed 
by propidium iodide (PI) uptake using flow cytometry with the acquisition channel FL-
2 (final concentration of PI 0.5 µg/ml). A total of 10.000 cells were acquired. Vehicle 
treated cells (control) were set as 100% and cell viability of allergen-treated cells 
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calculated using the cytometer analysis program. The concentration of allergens 
resulting in 75% of viability (CV75) was then calculated by linear interpolation using 
InStat software version 7.0 (GraphPad Software, La Jolla, CA, USA).  
 
Cell surface markers expression 
Cell surface markers expression was evaluated by FACS analysis. THP-1 cells were 
treated with the selected chemicals or DMSO as vehicle control. At different times after 
treatment, cells were centrifuged at 1500 rpm for 5 min, supernatants were collected 
for cytokines assessment, and cells stained for 30 min with specific FITC/PE-
conjugated antibodies against CD40, CD80, CD86 and HLA-DR (BD, Becton 
Dickinson, and ImmunoTools) or with isotype control antibodies at 4°C following 
supplier’s instructions. The intensity of fluorescence and the percentage of positive 
cells were analyzed using FACSCalibur flow cytometer, and data were quantified using 
CellQuest software (Becton Dickinson). Changes in surface markers expression are 
expressed as stimulation index (SI) calculated on the Geo Mean values (treated 
cells/vehicles treated cells). 
 
Cytokine production  
IL-8, IL-10, IL-18, IL-6 and IL-12p40 release were measured in THP-1 cells 
supernatants following time-course experiments (24, 48 and 72h). Cell-free 
supernatants were obtained by centrifugation at 1500 rpm for 5 min and stored at -20°C 
until measurement. All cytokines were assessed by a specific sandwich ELISA 
commercially available: IL-8, IL-6, and IL-12p40 from ImmunoTools (Friesoythe, 
Germany); IL-10 from eBioscence (Affymetrix, San Diego, CA) and IL-18 from MBL 
(Nagoya, Japan). Results are expressed as stimulation index (SI) of treated cells versus 
cells treated with vehicle.  
 
Western blot analysis 
The activation of PKC-βII in cell homogenates was assessed by Western blot analysis. 
Briefly, cells (3 x 106 cells) were treated with selected allergens (BZQ, BB, FITC, 
DEM, HCA and HDC) for different times: 5, 15, 30 and 60 minutes. Allergens were 
tested using the CV75. The strong contact allergen FITC was added to the previous list 
of chemicals tested to cover a broad range of potency, while one of the three weak 
contact allergen was removed (IMZ). At different times, cells were collected, washed 
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once with PBS, centrifuged, and lysed in 100 μl of homogenization buffer (50 mM 
TRIS, 150 mM NaCl, 5 mM EDTA pH 7.5, 0.5% Triton X-100, 50 μM PMSF, 2 μg/ml 
aprotinin, 1 μg/ml pepstatin, 1 μg/ml leupeptin, and 1X PhosphoStop) and denatured 
for 10 min at 100°C. The protein content of the cell lysate was measured using a 
commercial available kit (Bio-Rad). 10 μg of extracted proteins was electrophoresed 
into a 10% SDS–polyacrylamide gel under reducing conditions. The proteins were then 
transferred to PVDF membrane (Amersham, Little Chalfont, UK). The proteins were 
visualized using primary antibodies for Anti-PKC-βII (rabbit monoclonal Ab, dilution 
1:40.000, Abcam) and anti-β-actin (mouse monoclonal Ab, dilution 1:1000, BD) and 
developed using enhanced chemiluminescence (Clarity western ECL blotting 
substrates Bio-Rad). The image of the blot was acquired with the Molecular Imager Gel 
Doc XR (BioRad). The optical density of the bands was calculated and analysed by 
means of the Image Lab program for digital image processing (Version 4.0, Bio-Rad 
Laboratories).  
 
Data analysis 
All experiments were performed at least three times. Statistical analysis was performed 
using GraphPad InStat version 3.0a for Macintosh (GraphPad Software, San Diego, 
CA, USA). Dunnet’s test was used for multiple comparison analyses of variance. 
Differences were considered significant at p ≤ 0.05. 
 
Results 
Cell viability 
In preliminary experiments, cytotoxicity was established. In Table 1, CV75 results are 
reported (results are the mean of at least two independent experiments).  
 
Dose-response effects of the selected chemicals on cell surface marker expression 
following 24 h of treatment 
In Fig.1 the effects of the selected chemicals on CD80, CD86 and HLA-DR expression 
following 24 h of dose-response treatment are reported. Values are expressed as SI 
(GeoMean). Due to the high auto fluorescence of the FITC, which made it impossible 
to read at any channels available at the flow cytometer, this compound was discarded 
for the cell surface markers analysis. BZQ, BB, and HDC were able to induce a 
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statistically significant increase in the expression of CD86, while CD80 was up-
regulated after treatment with BB, DEM, and HCA. Only the extreme contact allergen 
BB was able to induce a statistically significant increase in HLA-DR expression.  
Effects of the selected chemicals on the cell surface marker expression in time course 
experiments  
In Fig.2 the effects of the selected chemicals on CD80, CD86 and HLA-DR expression 
following 24, 48 and 72 h of treatment are reported. All contact allergens were tested 
using ½ CV75 values calculated at 24h, as cytotoxicity was expected following longer 
incubation time. All contact allergens tested induced CD80 and CD86 expression with 
a different kinetics. In detail, the extreme allergens BB and BZQ induced CD86 and 
CD80 expression starting from 24h and 48h respectively but maintaining the expression 
of these markers above control until 72 h. DEM, a moderate allergen, was able to induce 
CD86 and CD80 expression starting from 48h. More interestingly was the effect of 
allergens on HLA-DR expression. This surface marker was induced only after treatment 
with the two extreme contact allergens BB, and BZQ.  
 
Effects of the selected chemicals on cytokines release in time-course experiments  
In Fig.3 the effects of the selected chemicals on IL-8, IL-10, IL-12 and IL-18 release 
following 24, 48 and 72h of treatment are reported. Also IL-6 release was assessed but 
it resulted always below the limit of detection for all contact allergens (data not 
reported). All the contact allergens tested were able to induce an increase in IL-8 
release, not statistically significant only for BB, confirming the ability of allergens to 
induce this cytokine in THP-1 (17–19). HCA and IMZ (weak allergens) failed to induce 
IL-10, IL-18, and IL-12 at all time point. The trend in increased IL-18 release was 
observed for the extreme allergen BB and the weak allergen HDC, that did not reach a 
statistically significance due to data dispersion. 
Overall, from the analysis of the selected cytokines, a clear picture does not emerge 
that could help to discriminate allergens based on their in vivo potency. The cytokines 
IL-12 and IL-18, typically associated with Th1 responses, are mainly induced by the 
two extreme contact allergens tested, respectively BZQ and BB. Also, the weak 
allergen HDC was able to induce an increase of these two cytokines but, however, it 
failed to induce the expression of HLA-DR (Signal 1) that is, on the contrary, 
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statistically significant expressed after exposure to BZQ and BB. Overall, results 
suggest that extreme allergens are able to fully activate naïve THP-1, used as surrogate 
of DC.  
 
PKC-βII activation 
In Figure 4 western blot analysis and densitometric analysis of PKC-βII activation are 
reported. Allergens were tested using the CV75. Densitometric analysis shows that all 
allergens, at concentrations that induce the same level of cell damage, were able to 
induce PKC-II activation with potency affecting the time of activation. The extremes 
contact allergens, respectively BZQ and BB, and the strong FITC were able to activate 
PKC-βII already at 5 min and the activation persisted until 60 minutes; while DEM 
(moderate) activated PKC-II at 15 minutes and the activation decreases more rapidly, 
after 30 minutes. Results reported clearly indicate that extreme and strong allergens are 
able to more rapidly activate PKC-II.  
 
DCs differentiation and maturation 
Data presented in Figure 5 indicate a different effect of allergens of different potency 
on THP-1 activation, with extreme allergens inducing a full maturation of cells, with 
up-regulation of both co-stimulatory and MHC class II molecules and release of 
cytokines important for Th1 cell activation (e.g. IL-12/IL-18). To demonstrate that 
indeed contact allergens induced full DC maturation, THP-1 cells were differentiated 
to immature DC and then exposed for 24h to three allergens of different potency: BB 
(extreme), DEM (moderate) and HCA (weak). In Fig. 6, Panel A, the differentiation of 
cells from THP-1 to immature dendritic cells (iDCs) is reported. THP-1 cells were 
treated for 5 days according to the protocol described by Berges et al. (16). After five 
days CD40, CD80, and CD86 were evaluated by flow cytometry and results are 
reported as % of positive cells. Results showed an increase in cell surface markers 
expression that indicates THP-1 differentiation. In Fig.6, Panel B, it is reported the 
maturation of immature DCs induced by a specific cocktail of maturation factors. Cell 
surface markers CD80, CD86 and HLA-DR were evaluated after 24h of exposure to 
rhIL-4 (3000 IU/ml), rhTNF-α (3000 U/ml), and ionomycin (200 ng/ml). CD80, CD86, 
and HLA-DR expression are reported as % of positive cells. As shown in Figure 6, 
Panel C, both DEM (moderate) and HCA (weak) were able to induce CD80 and CD86 
Jo
urn
al 
Pre
-pr
oo
f
 11 
cell surface expression otherwise failed to induce HLA-DR expression. On the 
contrary, the maturation of iDCs was successfully obtained only after treatment of iDCs 
with the extreme contact allergen BB as shown by the % of positive cells reported for 
all the cell surface markers assessed. These data support the hypothesis that only the 
extreme contact allergens have the capacity to induce a statistically significant increase 
of a full DCs maturation HLA-DR expression. 
 
Discussion 
The main aim of this work was to better understand the mechanism underneath the 
extent of DC maturation and activation induced by chemical allergens of different 
potency. Potency refers to the intrinsic property of a sensitizing chemical and is based 
on the concentration of chemical needed to induce a positive response (20). Allergens 
are known to vary significantly as much as 10.000-fold in relative sensitization potency 
with which they can induce skin sensitization. DCs, as APC, play a pivotal role in the 
initiation and regulation of immune responses, leading to specific T cell activation. 
During these processes, DCs undergo diverse phenotypical and functional changes such 
as up-regulated cell surface expression of co-stimulatory molecules and adhesion 
proteins (i.e. CD86, CD83, CD54, CD40, and MHC II antigens) (21). Maturation of 
DCs in response to sensitizing agents has been identified as one of the in vitro strategies 
to predict the sensitizing capacity of chemicals (22). Different approaches based on the 
use of dendritic-like cells cultures have been developed to mimic the maturation process 
of Langerhans cells. Among them, the THP-1 cell line is one of the most interesting 
alternatives because of its availability and abundance (23). Using this cell line, we have 
previously shown that exposure of THP-1 cells to allergens results in a dose-related 
release of IL-8, whereas exposure to irritants fails to induce IL-8 secretion (17,24).  
Human APCs express three different isoforms of MHC II molecules, denotes as 
human leukocyte antigen (HLA) -DR, -DQ, and –DP (25). HLA-DR represents a 
ligand for the T-cell receptor (TCR) and is involved in several immune and 
autoimmune disorders. Previous studies have indicated that for metal ions, considered 
as common allergens such as nickel, chromium and cobalt, the availability of surface 
HLA-DR is needed for T cell stimulation and to induce delayed hypersensitivity 
reactions (26). It is also well known that IL-12 and IL-18 play important roles in the 
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development of T helper type I (Th1) cells and are synergistic in the induction of IFN-
c by T-cells(27) . IL-18 has been demonstrated to favor Th-1 type immune response by 
enhancing the secretion of pro-inflammatory mediators such as TNF-α, IL-8, and IFN-
γ, and to play a key proximal role in the induction of ACD (28). Results presented in 
this work suggest that allergens of different potency differently modulated cell surface 
markers expression, with HLA-DR induced only by extreme allergens, which suggest 
their ability to induce a higher degree of DC maturation. In fact, only the exposure to 
extreme allergens was sufficient to provide the three signals required for T cell 
activation: Signal 1 or stimulation by up-regulating HLA-DR. Signal 2 or co-
stimulation by up- regulating CD80 and CD86, provided by the triggering of CD28 on 
the T cell by CD80 and CD86 molecules on the DCs. Signal 3 or polarization by 
inducing the release of IL-12 or IL-18, signals delivered from DCs to T cell that 
determine its differentiation Th1 phenotype. Moderate and weak allergens while 
inducing Signal 2 and in some instances, also Signal 3, failed to induced HLA-DR. 
Among the selected allergens, the behavior of the weak allergen HDC was different. It 
resulted to be more reactive compared to the other weak allergens tested. This behavior 
may be due to its structure, which shows similarities to citral and limonene, two weak 
chemical allergens toward which THP-1 cells are particularly reactive. Merckel et al. 
compared the reactivity of HDC and citral toward glutathione used as a classical model 
nucleophile in a semi-organic medium and in a microemulsion system: the two weak 
allergens react with the thiol group of glutathione, in both systems, to form identical 
adducts (29). 
Another important aim of this study was to characterize the role of PKC-β in 
chemical-allergen induced DC activation. We focused on PKC-βII as the available 
evidence indicates that PKC-βI and PKC-βII have different functional roles in 
monocytes: PKC-βI has been associated with the induction of apoptosis (30), while 
PKC- βII with proliferation and differentiation (11,22). We recently demonstrated a 
role of PKC-β in chemical allergen-induced CD86 expression and IL-8 release, two 
markers selectively up-regulated by chemical allergens (31,32), both in the human 
promyelocytic cell line THP-1 and in primary human DC (33). The ability of the PKC-
β pseudosubstrate to completely prevent also chemical allergen-induced CD80 (for 
BZQ) and HLA-DR expression, as shown by these new results obtained, support the 
central role of PKC-β also in the initiation of chemical allergen-induced DC maturation 
and activation. 
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Overall, our finding provides insights into the process of sensitization and strength of 
cell activation associated with allergens of different potency. The main aim of this 
work was to provide a mechanistic understanding able to support in vitro potency 
information, necessary for full replacement of animals in the broader perspective of 
classification and labeling of potential sensitizers. While the numbers of chemicals 
tested is limited, and additional compounds should be tested, results obtained support 
the notion that contact allergens of different potency are able to induce a different 
degree of activation of dendritic cells maturation with only extreme/strong allergens 
able to induce a statistically significant expression of the cell surface marker HLA-
DR, necessary for a full maturation of the dendritic cells. 
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Figures Legend 
 
Figure 1 – Effects of the selected chemicals on the expression of cell surface marker 
CD80, CD86 and HLA-DR in dose-response experiments. THP-1 cells were treated for 
24 h with increasing concentrations of the selected contact allergens, starting from CV75 
and with two 2-fold serial dilutions. Results are expressed as stimulation index (SI Geo 
Mean). The dotted line reported is set at 1.0 (control). Each value represents the 
mean ± SD, n = 3 independent experiments. Statistical analysis was performed with 
Dunnett’s multiple comparison test, with *p < 0.05, **p < 0.01 and ***p < 0.001 vs 
vehicle treated cells (control). DEM 160 μg/ml and IMZ 60 μg/ml resulted with cell 
viability less than 75%, despite the CV75 calculation (columns filled in grey colour). 
 
Figure 2 – Effects of the selected chemicals on the expression of cell surface marker 
CD80, CD86 and HLA-DR in time-course experiments. THP-1 cells were treated for 
24, 48 and 72 h with the selected contact allergens. Results are expressed as stimulation 
index (SI Geo Mean). The dotted line reported is set at 1.0 (control). Each value represents 
the mean ± SD, n = 3. Statistical analysis was performed with Dunnett’s multiple 
comparison test, with *p < 0.05, **p < 0.01 and *** p < 0.001 vs vehicle treated cells 
(control). 
 
Figure 3 – Effects of the selected chemicals on the cytokines release in time-course 
experiments. THP-1 cells were treated for 24, 48 and 72 h with the selected contact 
allergens. Results are expressed as stimulation index (SI). The dotted line reported is set at 
1.0 (control). Each value represents the mean ± SD, n = 3. Statistical analysis was 
performed with Dunnett’s multiple comparison test, with *p < 0.05, **p < 0.01 and *** p 
< 0.001 vs vehicle treated cells (control). 
 
Figure 4 –Western blot analysis and densitometric analysis of PKC-βII activation in 
THP-1 treated with contact allergens of different potency. THP-1 cells were treated for 
5, 15, 30 and 60 minutes. Results are expressed as immunoreactivity (% of control). The 
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dotted line reported is set at 100 (Control). Each value represents the mean ± SD, n = 3. 
Legend: C – control. 
 
Figure 5 – Effective contribution of PKC-β in chemical allergen-induced CD80, CD86 
and HLA-DR expression. THP-1 cells were treated for 2 h with a specific PKC-β inhibitor 
(PKC-β pseudosubstrate) and then BZQ 1.56 μg/ml and BB 2 μg/ml were added for 24, 48 
and 72h. Results are expressed as stimulation index (SI). The dotted line on the y-axis at 
1.0 of SI represents the threshold above which the chemical is considered positive. Each 
value represents the mean ± SD, n=3 independent experiments. Statistical analysis was 
performed with Dunnett’s multiple comparison test, with *,# p<0.05 and **,## p<0.01 vs 
vehicle treated cells (*) or vs allergens treated cells (#).  
 
Figure 6 – Dendritic cells (DCs) differentiation and maturation starting from THP-1 
cells. For DC differentiation, THP-1 cells were treated for 5 days wit rhIL-4 (1500 U/ml) 
and rhGM-CSF (1500U/ml) to acquire the properties of immature DCs (iDCs – Panel A). 
Mature DCs (mDCs) were then generated starting from iDCs by addition of rhIL-4 (3000 
U/ml), rhGM-CSF (1500U/ml), rhTNF-α (3000 U/ml), and ionomycin (200 ng/ml) or by 
exposure to contact allergen of different potency for 24h (Panel B and Panel C). CD40, 
CD80 and CD86 were assessed for the evaluation of cell differentiation (Panel A) while 
CD80, CD86 and HLA-DR expression were evaluated for the maturation process (Panel B 
and C). Each value represents the mean ± SD, n = 3. Statistical analysis was performed 
with Dunnett’s multiple comparison test, with *p < 0.05, **p < 0.01 and *** p < 0.001 vs 
THP-1 for differentiation experiments (Panel A) or vs iDCs for maturation experiments 
(Panel B and C). For each sample, 10.000 events were acquired and analysis was performed 
with a calculation of the % of positive gated cells. 
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Table 
 
Table 1. List of chemicals tested with the in vitro CV75 and the in vivo classification based on LLNA. 
CHEMICAL NAME CAS # ACRONYM 
CV75 
(μg/ml) 
LLNA potency 
category 
(EC3 % values*) 
Benzoquinone  106-51-4 BZQ 1.56 Extreme (0.01) 
Bandrowski's base 20048-27-5 BB 4.0 Extreme (0.02) 
Fluorescein isothiocyanate 
isomer I 
3326-32-7 FITC 250 Strong (0.14) 
Diethyl maleate 141-05-9 DEM 160 Moderate (5.8) 
-hexylcinnamaldehyde 101-86-0 HCA 40 Weak (12) 
Hydroxycitronellal 107-75-5 HDC 300 Weak (23) 
Imidazolidinyl urea 39236-46-9 IMZ 60 Weak (24) 
 
THP-1 cells were treated for 24h with increasing concentrations of the selected chemicals. Cell 
viability was assessed by PI staining. CV75 was calculated by linear regression analysis of data. Each 
value represents the mean of three independent experiments.  
* (15) 
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